Cancer Family
Head and Neck Neoplasm
CI-CAN-00000021Explore in graph →
Non-malignant1,572 active trials17 approved drugs142 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000021Explore in graph →
Clinical trials
6,373 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06118333 | A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) | active not recruiting | Phase 3 | 386 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT01266044 | Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia | active not recruiting | Phase 3 | 435 | M.D. Anderson Cancer CenterOTHER | 2 | Apr 16, 2026 |
| clinicaltrials |
| NCT02543320 | Neurofeedback in Decreasing Acute Radiotherapy-Induced Pain in Patients With Head and Neck Cancer | active not recruiting | N/A | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT02615275 | Bioelectrical Impedance Analysis in Estimating Body Composition in Patients With Stage I-IV Head and Neck Cancer Undergoing Radiation Therapy | active not recruiting | N/A | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT02662907 | Cough, Expiratory Training, and Chronic Aspiration After Head and Neck Radiotherapy | active not recruiting | N/A | 175 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)(LIBRETTO-001) | active not recruiting | Phase 1 / Phase 2 | 857 | Eli Lilly and CompanyINDUSTRY | 16 | Apr 16, 2026 | clinicaltrials |
| NCT02790853 | Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders | active not recruiting | Early Phase 1 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03114501 | Dyadic Yoga Intervention for Patient With Head and Neck Cancer Undergoing Radiotherapy and Their Family Caregivers | active not recruiting | N/A | 236 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05036330 | ProvoxLife Adoption Trends for Heat-Moisture Exchanger | active not recruiting | — | 130 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05232851 | A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer | active not recruiting | Phase 1 / Phase 2 | 20 | Mayo ClinicOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03323463 | Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma | active not recruiting | Phase 2 | 316 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04061980 | Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer | active not recruiting | Phase 2 | 24 | Providence Health & ServicesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04948437 | Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer | active not recruiting | — | 103 | National Taiwan University HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05463107 | Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid Cancer | active not recruiting | — | 50 | National Taiwan University HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04938609 | Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC) | active not recruiting | Phase 2 | 28 | Providence Health & ServicesOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05696548 | Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) | active not recruiting | Phase 2 | 51 | National Cancer Center Hospital EastOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT03916627 | Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | active not recruiting | Phase 2 | 65 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT02945631 | Quarterback 2b - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer | active not recruiting | N/A | 43 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05924256 | A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing | active not recruiting | Phase 2 | 88 | Fudan UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT01898494 | Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer | active not recruiting | Phase 2 | 519 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05318027 | ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy | active not recruiting | Phase 2 | 70 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05387915 | Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer | active not recruiting | Phase 2 | 33 | Emory UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05980000 | Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma(Rambro2) | active not recruiting | Phase 2 | 37 | Washington University School of MedicineOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03519048 | Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma(SURVEILL'ORL) | active not recruiting | Phase 3 | 197 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03410615 | Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC | active not recruiting | Phase 2 | 129 | Canadian Cancer Trials GroupNETWORK | 4 | Mar 24, 2026 | clinicaltrials |
| NCT02287311 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)(MABEL) | active not recruiting | Phase 1 | 38 | Baylor College of MedicineOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04211337 | A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer(LIBRETTO-531) | active not recruiting | Phase 3 | 291 | Loxo Oncology, Inc.INDUSTRY | 20 | Mar 19, 2026 | clinicaltrials |
| NCT04007744 | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 36 | Mayo ClinicOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06910566 | Factors Sustaining Tobacco Abstinence in Cancer Patients Treated With Radio-chemotherapy or Radiotherapy(TABAC STOP ORL) | active not recruiting | — | 100 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03665064 | Long Term Outcome Study in Patients With Pituitary Disorders | active not recruiting | — | 1,500 | University of AlbertaOTHER | 0 | Mar 16, 2026 | clinicaltrials |
| NCT06332092 | FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma(HNSCC) | active not recruiting | Phase 2 | 46 | Fulgent Pharma LLC.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03360890 | Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors(iPRIME) | active not recruiting | Phase 2 | 46 | University of ChicagoOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05538533 | Hypofractionated Preoperative Radiation for Head and Neck Cancers (HyPR-HN) | active not recruiting | N/A | 12 | Medical College of WisconsinOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04030455 | Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer | active not recruiting | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT03570021 | ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer(ESTIMABL3) | active not recruiting | Phase 3 | 352 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 3 | Mar 6, 2026 | clinicaltrials |
| NCT00581906 | Dynamic Contrast Enhanced MRI (DCE-MRI) Diffusion Weighted MRI (DW-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors | active not recruiting | — | 272 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT02597426 | Nasopharyngeal Carcinoma Post IMRT | active not recruiting | — | 108 | University Health Network, TorontoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07446036 | Prediction Model for Postoperative Headache After Transsphenoidal Pituitary Surgery | active not recruiting | — | 500 | Beijing Tiantan HospitalOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07435415 | Local Injection Methylene Blue Combined With Radiation in HNSCC Patients | active not recruiting | Early Phase 1 | 10 | China Medical University HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05261750 | Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer | active not recruiting | Phase 1 / Phase 2 | 15 | PT. Prodia Stem Cell IndonesiaINDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07434206 | Safety and Efficacy of Dexmedetomidine in Controlling Hemodynamics During Resection of Active Thyroid Secreting Tumors | active not recruiting | Phase 2 / Phase 3 | 80 | South Egypt Cancer InstituteOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04305366 | MicroRNA Markers in Head and Neck Cancers | active not recruiting | — | 225 | University of Colorado, DenverOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT03174275 | Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 2 | 39 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04713449 | Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survival Trial | active not recruiting | N/A | 643 | Rutgers, The State University of New JerseyOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07426874 | eHealth Support Tool to Improve Quality of Life in Head and Neck Cancer Survivors | active not recruiting | N/A | 30 | Royal College of Surgeons, IrelandOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04258813 | Onco-primary Care Networking to Support TEAM-based Care(ONE TEAM) | active not recruiting | N/A | 313 | Duke UniversityOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04868877 | Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | active not recruiting | Phase 1 / Phase 2 | 194 | Merus B.V.INDUSTRY | 9 | Feb 19, 2026 | clinicaltrials |
| NCT04967391 | Tumescence in HNC Skin Graft Reconstruction | active not recruiting | Phase 3 | 58 | University of California, DavisOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03822897 | De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma(EVADER) | active not recruiting | Phase 2 | 103 | Canadian Cancer Trials GroupNETWORK | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07407205 | Tumor Mutational Burden, Liquid Biopsy, Angiogenic Factors and DCE-MRI Perfusion in HPV-Negative Oropharyngeal Cancer | active not recruiting | N/A | 30 | Institute of Oncology LjubljanaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 17, 2026source: clinicaltrials